Introduction
The mammalian target of rapamycin inhibitors (mTORi) constitutes a new family of immunosuppressive drugs without direct tubular toxicity that have the capability to prevent acute allograft rejection and chronic allograft dysfunction. 1 mTOR is a unique kinase involved in survival, cell growth and proliferation. mTOR inhibition blocks the DNA and protein synthesis resulting in arrest of the cell cycle in lymphocytes, and thus blocking the immune response against the graft. 2 The molecular mechanism by which mTORi induces gonadal dysfunction, and infertility is not known clearly. The stem cell factor (SCF)/c-kit tyrosine kinase system is thought to be one of the most important hormone-receptor signalling pathways necessary for the proper development and maturation of functional germ cells and the maintenance of fertility. SCF/c-kit is involved in numerous functions, which include germ cell migration, cell adhesion, cellular proliferation and anti-apoptotic actions in the testis. 3 The male reproductive tissue has been found to contain high levels of FKBP12 (12-kDa FK506-binding protein, the immunophilin that binds to both tecrolimus and serolimus). 4 Recombinant FKBP12 was observed to enhance the curvilinear velocity of immature sperm, suggesting a role for FKBP12 in sperm motility initiation. As sirolimus binds to FKBP12 with high affinity, this might also have an important role in the development of gonadal dysfunction. The negative effect of sirolimus on fertility has been related with sexual hormone dysfunction, decreased volume of ejaculate and low sperm count or complete azoospermia in male recipients. 5 Besides the most common side-effects such as hypercholesterolemia, thrombocytopenia, adverse effects on wound healing and inhibition of lymphangiogenesis, some recent reports indicate that sirolimus negatively influences sex hormone levels and spermatogenesis in patients after solid organ transplantation. 6, 7 To our i n d i a n j o u r n a l o f t r a n s p l a n t a t i o n 9 ( 2 0 1 5 ) 1 1 9 -1 2 1 a r t i c l e i n f o experience no case report has been reported regarding the effect of sirolimus on spermatogenesis in Indian population. Fearing the tacrolimus induced nephrotoxicity, the patient was switched over to 2-drug containing therapy which included sirolimus (5 mg loading dose and 2 mg/day as maintenance dose) and MMF (1 g twice daily) after 4 years of transplant. The patient was father of 3-year-old child, when he started taking sirolimus. Three years later, the patient complained that his wife has not conceived after giving birth to her first child. No apparent cause of secondary infertility was found in his wife. When the patient himself was evaluated for the cause of secondary infertility, his hormone profile was found to be well within the normal range (Table 1) . But the sperm analysis of the patient revealed significant oligospermia, and all the sperm parameters were below the normal range (Table 2) . Soon after the patient was switched back to tecrolimus and MMF combination and the sperm analysis was repeated after nearly four months of sirolimus withdrawal, and all the sperm parameters were found to be in the normal range. His wife conceived 3 months after the discontinuation of sirolimus.
Case

Discussion
Sirolimus inhibits a pivotal multifunctional serine-threonine kinase (mammalian target of rapamycin), which mediates key signal-transduction pathways which control the cell cycle in variety of different cell types including T cell proliferation. 8 Feng et al. demonstrated that mTOR is a key regulator of spermatogonial proliferation. 9 The first data about rapamycininduced oligospermia were published in 2003, the authors presented a renal transplant recipient with oligospermia after 3 years of rapamycin treatment, and the cessation of rapamycin treatment for 7 months was followed up by complete normalization of the sperm parameters. 10 Considering the effect of sirolimus on the sex hormone levels, a casecontrol study data were published by Fritsche et al. in 2004, which showed lower testosterone values in 28 sirolimustreated patients compared with 28 non-sirolimus treated controls and a significant increase of FSH and LH. 11 But in our particular case, no sex hormone abnormality was observed.
The reversibility infertility has been analysed in a few studies as a hormone and semen parameter evaluation. After sirolimus withdrawal in kidney or heart-lung transplant recipients, hormone profile and sperm parameters regained normal values, and the young recipients could father a child. 12,13
Conclusion
The depression of spermatogenesis is a side effect of high importance in men, who are unmarried or wish to have a child, and the patients should be informed of this side effect. Because the effect is reversible, men on mTOR inhibitor treatment with a so far unsuccessful attempt to have a child, should be evaluated for temporary withdrawal of the drug (and possible substitution by an alternative immunosuppressant) to improve the probability to become father. Therefore the transplant recipients on mTOR inhibitor treatment should be monitored closely about their sexual function and fertility status.
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